{"nctId":"NCT01098032","briefTitle":"RenalGuard System and Contrast Media","startDateStruct":{"date":"2009-01"},"conditions":["Chronic Kidney Disease"],"count":294,"armGroups":[{"label":"Systemic alone therapy group","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Systemic alone therapy"]},{"label":"RenalGuard System group","type":"EXPERIMENTAL","interventionNames":["Device: RenalGuard system"]}],"interventions":[{"name":"RenalGuard system","otherNames":[]},{"name":"Systemic alone therapy","otherNames":["Sodium Bicarbonate and N-acetylcysteine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age \\>=18 years\n2. Chronic kidney disease (estimated glomerular filtration rate \\<=30 ml/min/1.72 m2) and/or\n3. Risk score for contrast nephropathy â‰¥11 (according to the Mehran score; J Am Coll Cardiol 2004; 44: 1393-1399)\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Heart failure (NYHA functional class III-IV)\n3. Acute pulmonary edema\n4. Acute myocardial infarction\n5. Recent (\\<=2 days) contrast media exposure\n6. Patients enrolled in concomitant studies\n7. Administration of theophylline, dopamine, mannitol and fenoldopam.\n8. End-stage CKD (patients on chronic dialysis)\n9. Systemic hypotension (systolic blood pressure \\< 100 mg/dl).\n10. Multiple myeloma","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Contrast-induced Acute Kidney Injury","description":"The primary outcome measure will be the rate of development of CI-AKI in the 2 study arms (number of participants). CI-AKI is defined as an increase in the serum creatinine concentration \\>=0.3 mg/dL from the baseline value at 48 hours after administration of the contrast media or the need for dialysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"146","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Kidney Injury and Major Adverse Events","description":"an increase in the serum creatinine concentration \\>=0.25% and \\>=0.5 mg/dl at 48 hours after contrast exposure","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Changes in the Serum Cystatin C Concentration at 24 and 48 Hours After Contrast Exposure","description":"Cystatin C is an alternative biomarker of kidney damage. Cystatin C seems to be superior to serum creatinine an identifying kidney function and damage.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Changes in the Urine and Serum NGAL Concentration After Contrast Exposure","description":"NGAL is a new biomarker which seems to be very promising in detecting kidney injury. prelimiary data suggest that urine and serum NGAL increase very early (within few horurs) after the occurrence og acute kidney damage. Therefore, NGAL may be a real marker of acute kidney injury.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"the Rate of Acute Renal Failure Requiring Dialysis","description":"occurrence of renal failure requiring dialysis represents the haard endpoint of the study. Actually this represents the worst clinical consequence of CI-AKI.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"The Rate of In-hospital Major Adverse Events (i.e. Acute Myocardial Infarction, c) Renal Failure Requiring Dialysis, and d) Acute Pulmonary Edema)","description":"Assessment of the rate of in-hospital major adverse events (i.e. acute myocardial infarction, c) renal failure requiring dialysis, and d) acute pulmonary edema) will give important informantion on the clinical relevance of prophylactic strategies in preventing CI-AKI","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"The Cost-effectiveness Ratio.","description":"Assessement of the cost-effectiveness ratio is important when testing a new strategy of both therapy and prophylaxis. The Renalguard system is more expensive than the conventional hydration regimen. The cost of RenalGuard system is approximately 800 $. This cost will be justified only if the system is more effective in preventing CI-AKI and improving the clinical outcome, expecially reducing the lenght of ospedalization and the rate of dialysis.","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":146},"commonTop":["Hypokalemia","Micturation"]}}}